间变性淋巴瘤激酶基因蛋白在不同级别胶质瘤中表达

我们应用免疫组化法检测间变性淋巴瘤激酶(ALK)基因蛋白在胶质瘤中的表达情况，分析其与胶质瘤分级、分期以及病人生存期的关系，为胶质瘤分级和预后判断找到新的指标。     

原发于骨骼肌的间变性大细胞T细胞淋巴瘤

目的：探讨骨骼肌原发的间变性大细胞淋巴瘤的临床病理特征和免疫表型。方法：采用常规制片和免疫组化(S-P)法检测1例（14岁）骨骼肌原发的间变性大细胞淋巴瘤。结果：肿瘤细胞CD30、ALK-1、CD45RO和CD45阳性；而CD20、EMA、S-100蛋白、desmin和CD68阴性。结论：本例为间变性淋巴瘤激酶（ALK）阳性的间变性大细胞淋巴瘤。骨骼肌原发的间变性大细胞淋巴瘤非常少见，诊断旱应先排除其它肿瘤和其它部位淋巴瘤累及骨骼肌。     

间变性淋巴瘤激酶基因在神经母细胞瘤中的致癌突变

晚期神经母细胞瘤是最难治的儿科肿瘤之一,它涉及多种遗传变异,包括高频率的N-myc基因扩增,染色体1p36和1q杂合子的丢失以及17q遗传物质的增加,这些都与神经母细胞瘤的发病机制有关。然而,由于缺乏有效分子靶点而阻碍了针对神经母细胞瘤治疗药物的研究进展。间变性淋巴瘤激酶(a     

小儿间变性大细胞性淋巴瘤

目的 :探讨小儿间变性大细胞性淋巴瘤的临床、病理及预后。方法 :对 17例外检和尸检小儿间变性大细胞性淋巴瘤的临床资料、病理切片和随访结果进行分析。结果 :间变性大细胞性淋巴瘤占小儿非霍奇金淋巴瘤的 12 8% ;临床表现主要是外周淋巴结肿大及皮肤损害 ,长期反复发热常见 ;病理特征为淋巴结部分受累 ,成片异形大细胞侵犯淋巴窦及副皮质区 ,免疫组化CD30强阳性 ;预后相对较好。结论 :小儿间变性大细胞性淋巴瘤并不少见 ,需与恶性组织细胞增生症、T区或多形T淋巴瘤、霍奇金淋巴瘤、蕈样霉菌病和转移性癌等鉴别。CD30、CD15、LCA和EMA免疫酶标检查对诊断及鉴别诊断十分有用。     

间变性淋巴瘤激酶克隆号1A4抗体在儿童髓母细胞瘤中的表达及其意义

目的探讨间变性淋巴瘤激酶(ALK)克隆号1A4抗体在儿童髓母细胞瘤中的表达及意义。方法采用NanoString技术和测序技术对浙江大学医学院附属儿童医院2014至2017年诊治的44例儿童髓母细胞瘤标本进行分子分型鉴定,同时应用免疫组织化学EnVision二步法检测ALK在44例髓母细胞瘤整张切片中的表达,统计分析蛋白表达与分子分型的关系。结果患者年龄范围0.5~13.0岁,平均年龄5.8岁。男性28例,女性16例。经典型31例,促纤维增生/结节型5例,广泛结节型3例,大细胞/间变型5例。44例儿童髓母细胞瘤除3例无确切划分亚型外,其余41例中5例为WNT型,12例为SHH型,9例为Group 3型,15例为Group 4型。44例肿瘤组织中13例ALK免疫组织化学阳性,阳性率为29.5%,其中强阳性6例、弱阳性7例。ALK蛋白表达与WNT型相关(P<0.01)。WNT型中特征性出现核旁点状阳性。结论ALK克隆号1A4免疫组织化学可辅助儿童髓母细胞瘤分子分型,强阳性且出现核旁点状阳性提示WNT亚型。     

间变性大细胞淋巴瘤的p80蛋白表达及其临床意义

目的 研究染色体易位ｔ（２;５）所形成的嵌合基因ＮＰＭ－ＡＬＫ的蛋白产物－－Ｐ８０蛋白在间变性大细胞淋巴瘤（ＡＬＣＬ）中的表达及与其亚型和预后的关系。方法 对已进行临床、病理和免疫学分析胼有随访资料的１９例ＡＬＣＬ用免疫组织化学ＡＢＣ法标记Ｐ８０蛋白。结果 Ｐ８０蛋白在１９例中有９例呈强阳性,组织学亚型为普通型和小细胞型,无１例为霍金样型（Ｐ〈０．０５）。Ｐ８０蛋白阳性病例的免疫学表型为Ｔ细胞性产     

荧光原位杂交检测石蜡包埋间变性大细胞淋巴瘤病例中ALK基因转位及其意义

目的　比较荧光原位杂交 (fluorescence in situ hybridization,FISH)和免疫组织化学在检测间变性大细胞淋巴瘤 (anaplastic large cell lymphoma,AL CL )中间变性淋巴瘤激酶 (anaplastic lymphomakinase,AL K)基因转位及其融合蛋白中的作用 ,并探讨 FISH在石蜡包埋组织中的应用。方法　采用双色FISH和免疫组织化学检测 2 2例石蜡包埋 AL CL病例中 AL K基因转位及其融合蛋白。结果　通过调整组织切片的酶消化时间等优化措施 ,成功地在石蜡切片上进行了双色 FISH实验 ;FISH和免疫组织化学均在 6 0 % (12 /2 0 )系统性 AL CL中检测到 AL K基因转位或融合蛋白 ,在 2例皮肤原发 AL CL中未检测到基因转位或融合蛋白 ,两种方法的符合率为 10 0 %。结论　 (1)在检测 AL CL中有无 AL K基因转位时 ,AL K蛋白免疫组化由于其简单、快捷、价廉成为一般情况下的首选方法 ;在具备 FISH条件时 ,也可以将 FISH作为首选 ;(2 )通过优化实验条件 ,可以在石蜡包埋组织上成功地进行 FISH实验。     

儿童及青少年间变性大细胞淋巴瘤预后因素的Meta分析

目的:应用Meta分析方法,对儿童及青少年间变性大细胞淋巴瘤(ALCL)一些有争议的临床预后因素进行定量分析,以客观评价这些因素对患者生存率的影响.方法:计算机检索中英文数据库,搜索从建库起至2020年12月31日间,儿童及青少年ALCL回顾性队列分析的文献.筛选文献并提取其中的生存数据,应用Review Manage...     

气管原发间变性大细胞淋巴瘤一例

患者男 ,12岁。因反复咳嗽 1个月 ,加重伴左胸及肩胛区疼痛 ,呼吸困难 4ｄ于 2 0 0 0年 5月 7日入院。胸部平片示左肺不张 ,纤维支气管镜检查见左主支气管距隆突 1ｃｍ处有新生物阻塞。术中见 :左肺不张 ,左侧胸腔内有少量淡黄色积液。切开左主支气管见一黄白色新生物完全阻塞管腔 ,冷冻组织检查诊断为肉瘤。肺门处见一直径 1.2ｃｍ的淋巴结 ,行左侧全肺及肺门淋巴结切除。病理检查 :全切肺两叶 ,大小为 13ｃｍ× 9ｃｍ× 7ｃｍ ,距主支气管断端 2 .5ｃｍ ,下叶支气管开口处见一有宽而短的蒂与管壁相连的新生物 ,直径为 3ｃｍ ,似有部分包膜…     

间变性大细胞淋巴瘤组织间变性淋巴瘤激酶及survivin蛋白表达及其临床意义

目的研究间变性大细胞淋巴瘤（ALCL）中间变性淋巴瘤激酶（ALK）蛋白及survivin蛋白的表达特点及其临床意义。方法应用免疫组织化学LSAB法检测ALK蛋白及survivin蛋白的表达。结果ALK蛋白在81例ALCL中有51例（63％）阳性,30例（37％）阴性。ALK阳性患者预后优于阴性患者（P〈0．05）。survivin蛋白在77例ALCL中均有不同程度的表达,其中高表达33例（42．9％）,低表达44例（57．1％）。survivin的表达与ALK蛋白表达无关（P〉0．05）。预后：Survivin高表达患者较低表达者差（P〈0．05）。在ALK蛋白阳性病例中,survivin高表达患者较低表达者差（P〈0．05）;ALK阴性病例中,survivin的表达状况与预后无关（P〉0．05）。Cox比例风险回归分析表明ALK的表达、体质性症状及survivin的不同表达状况对存活的影响有统计学意义（P〈0．05）,其中ALK的表达对生存的影响最大,survivin表达的影响最小。结论survivin蛋白在ALCL中的表达与ALK蛋白的表达不相关,是一个独立的指标,可有助于判断ALK阳性ALCL病例的预后。     

Targeting anaplastic lymphoma kinase in neuroblastoma

Over the last decade, anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase (RTK), has been identified as a fusion partner in a diverse variety of translocation events resulting in oncogenic signaling in many different cancer types. In tumors where the full‐length ALK RTK itself is mutated, such as neuroblastoma, the picture regarding the role of ALK as an oncogenic driver is less clear. Neuroblastoma is a complex and heterogeneous tumor that arises from the neural crest derived peripheral nervous system. Although high‐risk neuroblastoma is rare, it often relapses and becomes refractory to treatment. Thus, neuroblastoma accounts for 10–15% of all childhood cancer deaths. Since most cases are in children under the age of 2, understanding the role and regulation of ALK during neural crest development is an important goal in addressing neuroblastoma tumorigenesis. An impressive array of tyrosine kinase inhibitors (TKIs) that act to inhibit ALK have been FDA approved for use in ALK‐driven cancers. ALK TKIs bind differently within the ATP‐binding pocket of the ALK kinase domain and have been associated with different resistance mutations within ALK itself that arise in response to therapeutic use, particularly in ALK‐fusion positive non‐small cell lung cancer (NSCLC). This patient population has highlighted the importance of considering the relevant ALK TKI to be used for a given ALK mutant variant. In this review, we discuss ALK in neuroblastoma, as well as the use of ALK TKIs and other strategies to inhibit tumor growth. Current efforts combining novel approaches and increasing our understanding of the oncogenic role of ALK in neuroblastoma are aimed at improving the efficacy of ALK TKIs as precision medicine options in the clinic.     

Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center

PURPOSE: Anaplastic large cell lymphoma (ALCL), a CD30+ T-cell non-Hodgkin's lymphoma, represents only 2-8% of lymphoma overall. Information on the clinical findings of primary systemic ALCL in Korea is limited. Our aims were to report the clinical features and outcomes of primary systemic ALCL. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 36 adult patients diagnosed with primary systemic ALCL at Asan Medical Center from February 1995 through June 2006. RESULTS: Of 36 patients, 29 were male. The median age was 39 years (range, 17-67 years), and 26 (72%) presented with Ann Arbor stages III and IV. The most commonly involved extranodal sites were bone (n = 7) and soft tissue (n = 6). Thirty-two of all patients (89%) were treated with an anthracycline-based regimen including cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) as induction chemotherapy; 16 (50%) achieved complete remission (CR), and 13 (41%) achieved partial remission (PR). Median overall survival (OS) and event-free survival (EFS) were 49 and 17 months, respectively. Univariate analysis showed that performance status (p = 0.035), international prognostic index (IPI) (p = 0.025), and age-adjusted IPI (p = 0.034) were significant prognostic factors for OS, whereas anaplastic lymphoma kinase (ALK) expression did not affect OS (p = 0.483). CONCLUSION: Our retrospective analysis of Korean primary systemic ALCL patients showed that median OS was 49 months and overall response to CHOP was 91%. Performance, IPI, and age-adjusted IPI were predictors of OS, whereas ALK expression did not have prognostic significance.     

ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified

AIMS: Anaplastic large cell lymphoma (ALCL) is classically considered a clinicopathological entity separate from other nodal mature T-cell lymphomas (TCL). Recently, the anaplastic lymphoma kinase (ALK) protein was shown to identify a subgroup of nodal ALCL with an excellent prognosis, whereas ALK-negative ALCLs are more heterogeneous. The aim of this study was to investigate the clinicopathological parameters in relation to clinical behaviour of ALK-negative ALCL compared with other nodal mature TCL, i.e. peripheral TCL, unspecified (PTCL-NOS) and angioimmunoblastic lymphoma (AILT). METHODS AND RESULTS: Clinicopathological data of ALK-positive (n = 28) and ALK-negative (n = 46) ALCL; PTCL-NOS (n = 47); and AILT (n = 12) were analysed for their prognostic significance. While ALK-positive ALCL shows favourable clinical features and a good prognosis, ALK-negative ALCL, PTCL-NOS and AILT are all associated with high age groups, advanced disease stage, and poor prognosis (<45% 5-year survival). In multivariate analysis of overall survival time, performed in the combined group of ALK-negative nodal mature T-cell lymphomas, only age and the International Prognostic Index (IPI) remained independent prognostic parameters, while lymphoma subtype (ALCL versus PTCL-NOS versus AILT) gave no additional information. CONCLUSIONS: The distinction between ALK-negative ALCL and PTCL-NOS or AILT is of limited clinical relevance as they show comparable poor prognosis. In these lymphoma subtypes, only age and the IPI are of significant prognostic value.     

原发性淋巴结外间变性大细胞淋巴瘤临床病理分析

目的探讨原发性淋巴结外间变性大细胞淋巴瘤(anaplastic large cell lymphoma,ALCL)的病理形态、免疫表型特征及预后特点。方法对29例原发性淋巴结外ALCL进行形态学观察、免疫组化标记及随访,并结合相关文献进行讨论。结果本组淋巴结外ALCL共29例,男女之比为1.6∶1,平均年龄46.2岁。发生于皮肤12例、消化道7例、骨5例、口鼻黏膜3例、肺及乳腺各1例。29例患者中随访12例,随访时间3～45个月。29例均经外科手术切除局部病变或脏器,大部分再辅以化疗和放疗。12例随访病例中,手术切除病变后接受单纯化疗7例,放化疗者2例,未经放化疗者3例。其中8例死亡。ALCL组织学形态多样。免疫组化:29例ALCL均表达CD30,大多数表达CD3和(或)CD43(26/29),部分表达EMA、ALK-1、GranB和Perforin;不表达CKpan、CD20、CD79α、HMB45、CD68、CD15和CD117。结论发生在淋巴结外的ALCL并非罕见,临床表现无特异性,诊断依赖于组织病理学及免疫组化标记,淋巴结外(除外皮肤)的ALCL预后相对较差。该病应与弥漫性大B细胞淋巴瘤、霍奇金淋巴瘤...